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the statistician George Box once wrote:  
“ALL MODELS ARE WRONG BUT SOME ARE USEFUL”. 
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Cancer is a leading cause of death in economically developed countries and its 
incidence is continuously increasing mainly because of the aging and growth of the 
world population alongside cancer-causing behaviors and environmental pollution.  
Cancer is a multifactorial disease caused by combinations of genetic, 
behavioral, and environmental factors. It is characterized by disruptive cell division, a 
changes in cell morphology, and the ability of cancer cells to develop an invasive 
phenotype (1).  
Colorectal cancer (CRC) is a public health priority given the high incidence and 
mortality associated with this disease. It is the third most common cancer in men and 
Figure 1 Estimated new cancer cases and deaths worldwide for leading cancer sites. Source: 
GLOBOCAN 2008 (modified from: Jemal et al. CA: a cancer journal for clinicians, 2011) 
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the second in women worldwide, the second most common cause of death from 
cancer in Europe and the fourth worldwide with over 1.2 million new cancer cases and 
608,700 deaths estimated to have occurred in 2008 (Figure 1) (2-4). Although, it is 
among the most preventable cancers, it is frequently diagnosed only when symptoms 
become apparent or troublesome. By that time, CRC may be in an advanced stage. 
Surgery continues to be the mainstay of treatment, with the greatest influence 
on survival. However, while surgery excises  detectable tumor tissues, occult 
metastases frequently produce disease recurrences (5). Recurrence rates range 
between 10% for tumors confined to mucosa (stage I) and more than 50% for tumors 
with metastases to regional lymph nodes (stage III) (6). 
According to the model developed by Vogelstein and colleagues (Figure 2), CRC 
arises through a series of genetic alterations of the gastrointestinal epithelial cells that 
disrupt normal mechanisms of proliferation and self-renewal (7). Such mutations drive 
the transition from healthy colonic epithelia to increasingly dysplastic adenoma and 
finally to cancer. 
 
 
Figure 2 A genetic model for colorectal tumorigenesis. 
(from: Fearon E. and Vogelstein B., Cell, 1990) 
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Stem cells of the gastrointestinal tract may represent a natural target of tumorigenic 
mutations, due to both their long life span and to their capacity for self-renewal. The 
so-called “cancer stem cell model” proposes that, similar to normal tissues, cancers are 
also hierarchically organized (8). Only rare tumor cells, endowed with self-renewal and 
differentiation capacity, defined as “cancer stem cells” (CSCs), are postulated to be 
capable of tumor initiation and maintenance (Figure 3). In contrast, the majority of 
cells representing the tumor bulk do not possess the capacity to transplant cancers in 
immunodeficient hosts. 
Conventional cancer therapies rely on the eradication of all tumor cells, but if 
the putative CSCs may be less sensitive to these therapies, then they will remain viable 
after therapy. The CSC hypothesis implies that to achieve a complete and durable 
remission the therapy has to eradicate the CSCs (Figure 4). 
Figure 3 Two alternative models have been put forward to explain how tumours initiate and develop. 
The stochastic model (a) proposes that tumour cells are heterogeneous, but that virtually all of them 
can function as a tumour-founding cell, although this might happen only rarely. Conversely, the 
hierarchical model (b) implies that only a small subpopulation of tumour stem cells can proliferate 
extensively and sustain the growth and progression of a neoplastic clone. (modified from Reya T., 
Nature 2001) 
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The development of novel compounds able to specifically target CSC 
populations currently represents a major challenge in anti-cancer drug discovery. An 
absolute prerequisite for the achievement of this goal is represented by the 
establishment of reliable CSC models in vitro. Established cell lines are largely used for 
screening of novel anti-cancer compounds. However, whether they do comprise CSC 
populations resembling those of primary tumors, remains highly debated. 
 
 
 
 
Figure 4 A new treatment strategy that specifically targets cancer stem cells, when combined with 
current treatments, may lead to a more complete and durable regression of malignant cancers. 
(modified from Reya T., Nature 2001) 
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1.1 Colorectal Cancer 
 
1.1.1 Anatomy 
 
The colon consists of five distinct anatomical sections. Starting from the ileum, 
the final section of the small intestine, the colon, may be divided in cecum, ascending 
colon, transverse colon, descending colon, and sigmoid colon (9).  
 
Figure 5 Structure of the colon – (Upper Left) Different segment of the colon. (Lower right) Structure 
of the colon wall. (Lower Left) Structure of the crypt of Lieberkühn. (modified from: Adams Atlas 
Anatomy; Rizk and Barker, WIRE 2012) 
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Unlike other parts of the gastrointestinal system (GI), the colon is not primarily 
responsible for the absorption of food and nutrients. Instead, its main function is to 
extract water and salt from solid waste before it arrives, through the rectum, to the 
anus and is then excreted. A minor role in the absorption of specific nutrients, 
including vitamins, and, more specifically, vitamin K, has also been reported (9). 
Colon is organized into four histologically distinct layers. The epithelial layer is 
made up of a single sheet of columnar epithelial cells, which form finger-like 
invaginations into the underlying connective tissue of the lamina propria to form the 
basic functional unit of the intestine, the crypt, also called gland of Lieberkuhn (Figure 
5) (10). Each crypt contains around 2000 cells and approximately 14,000 crypts per 
square centimeter are located in the adult human colon with a total renewal turnover 
rate of five days. 
This process is fuelled by adult multipotent stem cells placed at the bottom of 
each crypt and engaged in a crosstalk with perycryptal myofibroblasts, closely 
adherent to the basal lamina surrounding the crypt (11). During asymmetric division, 
these cells undergo self-renewal and generate a population of transit-amplifying cells 
that occupy the lower two thirds of the crypt. Upon migration upward from the crypt, 
these cells proliferate and differentiate into one of the epithelial cell types of the 
intestinal wall that constitute the top third of the crypt. The terminally differentiated 
cells are continually extruded into the lumen (12).  
There are three major terminally differentiated epithelial lineages in the colon: 
the colonocytes, also termed absorptive enterocytes; the mucus-secreting goblet cells; 
and the less abundant enteroendocrine cells (Figure 5, lower left panel). Finally, 
Paneth cells, functionally similar to neutrophils, are scattered at the bottom of the 
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crypt only in the small intestine epithelium and do not follow the upward migratory 
pathway (12).  
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1.1.2 Risk factors for colorectal cancer 
 
Primary predisposition to CRC is usually genetic but other conditions and 
factors that could lead to increased risk of CRC are: 
 Age: CRC incidence increases with age. CRC rarely affects people younger than 
50. CRC in young adults is usually associated with conditions of familial 
predisposition. 
 Familial clustering: subjects with relatives that have been affected by familial 
adenomatous polyposis (FAP) or by hereditary nonpolyposis CRC (HNPCC) have 
an increased risk of developing CRC. 
 Smoke: long-term smoking increases CRC incidence (13). 
 Lifestyle: Current dietary recommendations to prevent colorectal cancer 
include increasing the consumption of whole grains, fruits and vegetables, and 
reducing the intake of red meat(14, 15).The evidence for a preventive role of 
fibers fruits and vegetables however, is poor (15). Physical activity can 
moderately reduce the risk of colorectal cancer (16). 
 Environmental factors: People living in industrialized areas have a higher risk of 
developing CRC(17). 
 Presence of chronic inflammatory processes of the intestine, such as Crohn's 
disease and ulcerative colitis is associated with CRC development. About 1% of 
patients with CRC have a history of ulcerative colitis. The risk of developing CRC 
is directly related to the severity of intestinal mucosal damage and the extent 
of inflammation. The risk of developing CRC in subjects with Crohn's disease is 
lower than patients with ulcerative colitis (18, 19). 
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 Polyps of the colon: Polyps are a risk factor for CRC, particularly if they are 
adenomatous. Siblings and parents of patients with adenomatous colorectal 
polyps have a 1.78 relative risk for developing CRC. The age at the time of polyp 
diagnosis is an important prognostic factor for the risk of cancer development. 
Siblings of patients with adenomatous polyps diagnosed before age 60 have a 
2.59 relative risk for developing CRC. Polyp size and histology are directly 
related to the risk of CRC, with villous polyps larger than 2 cm having a 50% 
greater chance of containing cancer cells than smaller or nonvillous polyps (20, 
21). 
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1.1.3 Prognostic factors 
 
Outcome prediction in CRC usually relies on histopathological evaluation of 
tissue samples obtained during surgical removal of the primary tumor. Currently, the 
most important conventional prognostic factors are histological tumor grade and 
tumor stage of disease at the time of diagnosis (pTNM -UICC-, Astler-Coller, or 
Dukes’s), including depth of tumor invasion, involvement of regional lymph nodes, and 
metastatic spread to distant organs. Such approaches have been shown to be 
prognostically valuable (22).  
In addition to these classic clinicopathological parameters, molecular markers 
of prognostic and predictive relevance are continuously being proposed for a wide 
variety of tumors including CRC (23). 
Staging reflects the extent or severity of cancerous disease based on the 
extension of the tumor and its spread in the body. Establishing the stage of the disease 
helps to plan treatments and to predict the likely outcome or course of the disease.  
Different staging systems have been developed. The Dukes' classification, 
proposed by Dr. Cuthbert E. Dukes in 1932, focuses on tissue infiltration and presence 
of lymph node involvement and distant metastases (24). The original Dukes 
classification of 1932 described the staging of rectal carcinoma only but is also usually 
applied to carcinomas of the colon. It originally included three simple stages, A to C. 
Stage D was added later. Dukes’ stages of cancer are the following: 
 
Dukes' A: Invasion into but not through the bowel wall (90% 5-y survival) 
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Dukes' B: Invasion through the bowel wall but not involving lymph nodes (70% 5-y 
survival) 
Dukes' C: Involvement of lymph nodes (30% 5-y survival) 
Dukes' D: Widespread metastases  
 
The TNM classification is the most widely used. The TNM staging system for all 
solid tumors was devised by Pierre Denoix between 1943 and 1952, considering size 
and extension of the primary tumor, lymphatic involvement, and the presence of 
metastases to classify cancer progression. Degree of tissue infiltration, discriminating 
between the invasion of the mucosa only, muscle layer or sierosa is accurately 
analyzed. 
While “T” stands for the size of the tumor and whether it has invaded nearby 
tissues, “N” refers to regional lymph node invasion, and “M” to distant metastases 
(following table, Figure 6, and Panel 1) (25). 
The American Joint Committee on Cancer and the International Union Against 
Cancer (AJCC/IUAC) has developed an additional staging system partially using TNM 
scoring system to describe the extent of disease progression in cancer patients: 
 
AJCC/IUAC stage TNM stage TNM stage criteria for colorectal cancer 
Stage 0 Tis N0 M0 Tis: Tumor confined to mucosa; cancer-in-situ 
Stage I T1 N0 M0 T1: Tumor invades submucosa 
Stage II-B T2 N0 M0 T2: Tumor invades muscularis propria 
Stage II-A T3 N0 M0 T3: Tumor invades subserosa or beyond (without other organs involved) 
Stage II-B T4 N0 M0 T4: Tumor invades adjacent organs or perforates the visceral peritoneum 
Stage III-A T1-2 N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T1 or T2. 
Stage III-B T3-4 N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T3 or T4. 
Stage III-C any T, N2 M0 N2: Metastasis to 4 or more regional lymph nodes. Any T. 
Stage IV any T, any N, M1 M1: Distant metastases present. Any T, any N. 
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Panel 1 – Colon and rectal cancer staging by AJCC 
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In recent years, several studies have shed light on the importance of the tumor-
infiltrating immune cells as an essential prognostic factor for patients’ disease-free, 
overall survival, and clinical response to adjuvant therapies (22, 26, 27). Importantly, 
tumor cells can express tumor associated antigens and become targets for T cell-
mediated adaptive immune response (28). In particular, Galon and colleagues (22, 29) 
found that the analysis of CRC immune infiltrate represented a better predictor of 
patient survival than histopathological methods currently used to stage CRC.  
First, they showed that a strong in situ immune reaction in the tumor 
correlated with a favorable prognosis regardless of the local extent of the tumor and of 
invasion of regional lymph nodes (Stage I, II, and III). Second, they defined an 
Figure 6 Stages of Colon Cancer: Stage I. The cancer is contained only in the inner layers of the colon 
wall. There is no spread to adjacent lymph nodes or other organs; Stage II. The cancer has grown 
through all the layers of the bowel wall, but not to lymph nodes or other organs; Stage III. The cancer 
has spread to adjacent lymph nodes, but not to other organs; Stage IV. The cancer has spread to other 
organs such as the liver or the lungs. (modified from: National Cancer Institute) 
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“immune-score” reflecting the CD8+/CD45RO+ T cell density in the center of the tumor 
and at the invasive margin. They found that the immune-scoring was significantly 
superior to the TNM staging. Indeed, patients with low immune-score had severe 
prognosis, while patient with high immune-score experienced low recurrence rates 
(22). Finally, they hypothesized a central role of memory T cells in the control of tumor 
recurrence.  
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1.1.4 Therapy 
 
Surgery is the mainstay of treatment of localized disease with the greatest 
influence on survival. Over 70% of patients with stages I–III CC can be cured by surgery 
alone. On the other hand, the use of adjuvant chemotherapy at different stages of the 
disease is debated.  
Over 20 years of clinical trials have led to the acceptance of 5-
fluorouracil/leucovorin (5FU/LV) as the standard of care for patients with node-
positive CRC. A number of clinical trials were conducted in the 80s and 90s to address 
the schedule-dependent mode of action of 5FU in order to increase efficacy while 
reducing toxicity. At present time, adjuvant chemotherapy is recommended for stage 
III and high-risk stage II cancers.  
All in all, in stage II CRC, 60% to 70% of patients are cured with surgery alone, 
and 15 to 20% relapse despite adjuvant chemotherapy. In stage III CRC, 40 to 50% of 
patients are cured by surgery, while approximately 35% of patients will relapse, 
despite adjuvant chemotherapy (30). 
In the metastatic setting, patients are treated with standard first- and second-
line chemotherapy regimens, 5-FU/LV with oxaliplatin (FOLFOX) and 5-FU/LV with 
irinotecan (FOLFIRI), eventually in combination with the anti–vascular endothelial 
growth factor (anti-VEGF) monoclonal antibody bevacizumab, and/or the anti–
epidermal growth factor (anti-EGFR) antibodies, cetuximab or panitumumab. 
Frequently, patients are sequentially administered all these treatments due to the 
inability to predict responsiveness, except for EGFR inhibitors, which are usually 
omitted in patients with tumors harboring KRAS mutations. (30).   
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1.2 The Cancer Stem Cell Model 
 
1.2.1 A paradigm shift 
 
Most tumors appear to contain morphological and functionally heterogeneous 
populations of cancer cells (31). This observation is traditionally explained by 
postulating variations in tumor microenvironment and coexistence of multiple genetic 
subclones created by progressive and divergent accumulation of independent somatic 
mutations (32). This implies that tumor tissue grew from the expansion of 
heterogeneous clonal populations and, also, that virtually all cells within the tumor 
have the capacity to regenerate and propagate cancer. 
Since last decade two models for the development of solid tumors have been 
proposed: the “conventional” stochastic model suggests an accumulation of successive 
mutations and the clonal selection of tumorigenic cells, whereas a second model can 
be referred to as the hierarchical model, which postulates cancer stem cells as the 
origin of cancer. 
In 1997, Dick and colleagues (33), studying human acute myeloid leukemia 
(AML), discovered that only a small subset of cells is capable of to transfering AML 
from patients to immunodeficient mice regenerating all types of cells that characterize 
AML. Stem cells are defined as cells that have the ability to perpetuate themselves 
through self-renewal and to generate mature cells of a particular tissue through 
differentiation (8). Because stem cells are the only long-lived cells in many tissues, 
especially in renewing systems such as human gut epithelia, they persist long enough 
in the tissue to undergo a prolonged sequence of successive mutation and selection 
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cycles inherent with the concept of multistage carcinogenesis (32). These are the bases 
of the original concept of “cancer stem cells” (CSC). 
CSCs do not necessarily originate from the transformation of normal stem cells 
but they may arise from a restricted number of progenitors or more differentiated 
cells that have acquired self-renewing capacity. The original rigid interpretation of the 
model presents malignancy as a hierarchically organized tissue with a CSC population 
at the top that generates the more differentiated bulk of the tumor cells. In this model, 
the differentiated tumor cells have lost their clonogenic ability and their capacity to 
drive long-term progression of the malignancy (34). 
CSCs were described having three common characteristics: i) they are the only 
cells in the tumor endowed with tumorigenic potential when xeno-transplanted into 
immunodeficient mice, ii) they are capable to recreate the full phenotypic 
heterogeneity of the original tumor, and iii) they are characterized by the expression of 
a distinctive surface markers profile that allows to isolate them from the non-
tumorigenic tumor cells. 
Stem cell biology could provide new insights into cancer biology due to the 
analogies existing between normal stem cells and tumorigenic cells. In fact, a growing 
body of evidence is increasingly supporting the idea that at least some human cancers 
may be considered as a stem cell disease (12). 
An important reason for the widespread interest in the CSC model is that it can 
comprehensibly explain essential, poorly understood clinical events, such as therapy 
resistance, minimal residual disease, and tumor recurrence (34). The observation that 
cancer growth can be sustained by a minor subpopulation of tumor cells with unique 
functional properties could also assist in the design of new and more effective 
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antitumor treatments. According to the CSC model, therapeutic approaches that do 
not eradicate the CSC compartment are likely to achieve little success. Indeed, they 
might kill the majority of tumor cells, resulting in tumor shrinkage, but ultimately fail 
to prevent disease relapse and metastatic dissemination (8). Furthermore, antitumor 
treatments are generally screened based on their capacity to induce a clinical response 
(i.e., a dramatic regression, either complete or partial, of the tumor lesion). This 
approach, however, tends to select for treatments that are active on the bulk of tumor 
cell population but not necessarily on CSCs. New approaches for the preclinical 
evaluation of treatment efficacy will then need to be devised (32). 
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1.2.2 Cancer Stem Cells in CRC 
 
The observation that the accumulation of mutations involving oncogenes and 
tumor suppressor genes accompanies the progression of the disease along the 
adenoma– carcinoma sequence induced Fearon and Vogelstein to formulate in the 
1990s the “adenoma–carcinoma model”. They postulated that the neoplastic process, 
initiated by APC or β-catenin mutations and tumor progression, results from the 
sequential mutation of other genes, such as K-Ras and p53, in the context of a growing 
genomic instability. This model has been further refined and the studies performed on 
relatively rare inherited cases led to the identification of genetic alterations that play a 
major role in the development of sporadic CRC. Recent studies have shown that the 
mutations that were found in human colorectal cancer generate intestinal carcinomas 
in mice only when forced to occur in stem cells (35). According to the cancer stem cell 
hypothesis, it can be assumed that the first mutational hit occurs in a colonic SC 
located at the crypt bottom that, being long-lived, can accumulate oncogenic 
mutations over years or decades. Eventually, the entire niche will be colonized by 
mutant stem cells, and the crypt will be filled with their progeny (36). The proliferating 
cancer cells will be subjected to further changes that may result in cancer progression. 
 
A number of studies have been conducted that provide evidence for the 
existence of colon CSCs and demonstrate that the CRC tumorigenic cell population can 
be FACS-purified by virtue of their cell surface phenotype. In particular, CSC 
populations have been identified in primary tumors either by CD133 expression (37, 
38), or by co-expression of CD166/CD44 (39). More recently, normal and malignant 
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colonic cells with a higher activity of the detoxifying enzyme aldehyde dehydrogenase 
1 (ALDH1) have showed stem cell properties. The isolation of CRC cells with higher 
ALDH1 activity was associated with higher tumorigenic capacity after xenografting in 
immunodeficient mice (40). 
Recently, Clevers and colleagues demonstrate that Lgr5+ cells are the crypt 
stem cells, and also that deletion of APC in these cells leads to neoplastic 
transformation generating adenoma structures (35, 41). At the same time, Zhu et al. 
showed that CD133+Lgr5+ co-expressing cells are responsible for the formation of the 
entire intestinal epithelium, and are susceptible to transformation (42). 
Therefore, identification of biomarkers for human CRC-SCs has the potential to 
improve the understanding of the mechanism underlying tumor growth and 
progression. 
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1.2.3 Colorectal Cancer Stem Cell Markers 
 
Colon CSCs were originally identified through the expression of the CD133 
glycoprotein using an antibody directed to its epitope AC133. Other cell surface 
markers, such as CD44, CD166, Musashi-1, CD29, CD24, leucine-rich repeat-containing 
G-protein-coupled receptor 5 (Lgr5), and aldehyde dehydrogenase 1 (ALDH1), have 
been proposed since (43). 
 
CD133 (Prominin-1) 
CD133 (prominin-1) is a glycoprotein with an N-terminal extracellular domain, 
two large extracellular loops, which are strongly N-glycosylated, and an intracellular C-
terminus (44). The AC133 antigen, which represents a hyper-glycosylated version of 
CD133, is primarily expressed in stem and progenitor cells such as embryonic 
epithelium, brain stem cells, hematopoietic stem cells, and in cancers such as leukemia 
and retinoblastomas. (45) 
CD133 was first reported as a putative CRC-SC marker in the studies conducted 
by O’Brien et al. (37) and Ricci-Vitiani et al. (38) by evaluating the tumorigenic 
potential of freshly isolated CD133 expressing cells from human CRC specimens and 
injecting them into immunodeficient mice. Cells bearing the glycosylated epitope 
AC133 were the only able to generate tumors in mice, whereas their negative 
counterparts were not. More importantly, tumor xenografts generated by CD133+ 
CRC-SCs displayed the same morphologic features of the parental tumor reproducibly 
maintained upon serial transplantation, suggesting that the molecular heterogeneity of 
the original tumor was effectively recapitulated.  
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Subsequent studies, however, have shown that in both mouse and human 
colorectal cancers, CD133 expression is not restricted to rare cell subsets, but it is 
detectable in relatively large numbers of tumor cells, irrespective of their 
tumorigenicity. Furthermore, Shmelkov et al. demonstrated that both, CD133+ and 
CD133- cells have tumor seeding capacity in metastatic colon cancers, thus questioning 
the validity of CD133 as a marker (46). 
 
CD44 
Proteins encoded by the CD44 gene constitute a large family of at least 20 
isotypic variants, based on differential splicing and post-translational glycosylation. 
CD44 is a single transmembrane protein with a short intracellular domain, whose 
expression is regulated by the Wnt signaling pathway via β-catenin. CD44 has been 
described as part of the CSCs signature for colon carcinomas (39), head and neck 
carcinomas, non-small cell lung cancer, hepatocellular carcinoma, and breast cancer 
(45). 
CD44 is one of the best described markers of CSCs in numerous different 
malignancies, raising the question as to whether this abundant protein fulfills essential 
tasks in CSCs (45). 
 
CD166 
CD166 (also called activated leukocyte cell adhesion molecule ALCAM) is a 
highly conserved multidomain transmembrane glycoprotein of the immunoglobulin 
superfamily and is widely expressed in a variety of normal tissues. This molecule 
mediates homotypic and heterotypic interactions between cells. It plays a role in the 
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development of different tissues, for example in neurogenesis and haemotopoiesis, 
and it participates in the mechanisms of the immune response (47). It is also expressed 
in various malignant lesions, such as melanoma and esophageal, gynecologic, prostate, 
and pancreatic cancers, and its expression is associated with diverse outcomes in 
different tumors (47). CD166 expression is reported to be significantly elevated in CRC 
as compared with normal mucosa. However, inconsistent data exist regarding the 
prognostic significance of CD166 expression in CRC (23, 48, 49). 
 
CD24 
CD24 is a glycosylated adhesion molecule that was first described in normal B 
and T cells. It is a protein anchored into the plasma membrane via glycosyl-
phosphatidyl-inositol and interacts with P-selectin. CD24 is implicated in T cell 
costimulation, regulation of T cell homeostatic proliferation, growth and 
metastatisation of cancer cells, and apoptosis. CD24 ligands are organ-specific and 
could include CD24 itself, P-selectin, and fibronectin. The lack or low cell surface 
expression of CD24, concomitant with high expression of CD44 has been associated 
with a CSC phenotype in breast cancer. Pancreatic CSCs, instead, are defined by the 
expression of both CD24 and CD44. CD24 expression is a prognostic marker for 
ovarian, breast, prostate, and non-small cell lung carcinomas (45). Expression of CD24 
in mammary carcinoma cell lines resulted in an enhancement of tumorigenic and 
metastatic potentials of the cells (50). Furthermore, Yeung and colleagues, studying 
human CRC cell lines, proposed the co-expression of CD44 and CD24 as an additional 
CSC phenotype (51). 
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Lgr5 
The Wnt signaling pathway regulates the proliferative activity of intestinal crypt 
cells. Mutations of the Wnt negative regulator adenomatous polyposis coli (APC) 
activate the Wnt pathway that induces transcription of genes via transcription factors 
of the T-cell factor (Tcf) family. Lgr5/Gpr49 is one of the Tcf4 target genes that appears 
to be specifically active in the small cycling cells that are interspersed between the 
Paneth cells of the small intestine. In studies of genetic mouse models, Lgr5-positive 
cells were found to represent the long-lived stem cells of the small intestine and colon 
(41, 52). Deletion of the APC gene, a central regulator of β-catenin stability, in Lgr5-
positive cells results in fast and progressive transformation (45). Therefore, it has been 
suggested that Lgr5 might represent good marker for the characterization and the 
isolation of human CRC-SC (53, 54). 
 
While phenotypic characterization of CSCs derived from colorectal cancers is 
still debated, still unclear is whether these surface proteins represent mere surrogate 
markers or play specific roles in the regulation of CSC functions. 
- 26 - 
 
1.2.4 Clinical implications of the CRC CSC model 
 
The term CSC refers to cancer cells sharing discrete properties with normal 
stem cells including self-renewal and the ability to initiate a hierarchy of more 
differentiated cells unable to self-renew. Based on these properties, the CSC 
hypothesis makes two important predictions: (i) CSCs are required for tumor growth 
and metastasis; and, (ii) elimination of CSCs is required for cure (8). 
One of the major concerns in the use of cytotoxic agents is that they are 
designed to kill actively proliferating cells, which represent the bulk of the tumor cell 
population. Thus, even if antitumor strategies lead to shrinkage in tumor size and 
disease remission, they fail to prevent relapse due to CSCs survival. According to the 
CSC model, tumor growth is sustained by a small population of cells that current 
therapeutic measures fail to eradicate. A CSC-specific therapy will not cause tumor-size 
reduction in short term, but it will prevent successive regrowth. In order to 
successfully eradicate tumors, anti-cancer treatments should primarily target CSC 
subsets. (55)  
Experimental data provide evidence that failure of chemo- and radiotherapy 
might be due to CSCs resistance to treatment (56-58). Indeeed, CSCs have been found 
to express high levels of DNA repair mechanisms (59, 60), detoxifying enzymes, such as 
aldehyde dehydrogenase-1 (ALDH1) (61), and molecular pumps (62-64). Furthermore, 
due to their relatively quiescent state they represent unlikely targets for anti-
proliferative treatments. The designs of new therapeutic approaches specific for CSCs 
are therefore needed. 
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In support of this hypothesis, Todaro et al. recently demonstrated that CD133+ 
CRC-SCs produce interleukin-4 (IL4), an autocrine growth factor that promotes tumor 
resistance to the chemotherapeutic agents 5FU and oxaliplatin. On the basis of this 
finding, they devised a strategy to sensitize the CRC-SCs to chemotherapy through the 
targeting of IL-4 (65). The ‘‘malignant’’ microenvironment has proven essential for the 
maintenance and development of CSCs. Interruption of the crosstalk network between 
the elements of the niche and CSCs will dramatically affect their capacity to support 
tumor growth and metastatic potential.  
However, although CSCs have been postulated to be responsible for decisive 
pathophysiological steps, directly affecting clinical behavior of cancers, limited data 
unequivocally support this concept. Most recently, a number of studies have begun to 
evaluate the role of CSCs in determining patients’ prognosis (31). 
In breast cancer, immunohistochemical quantification of CD44+/CD24−/low 
CSC phenotype did not correlate with tumor progression or overall survival, but a 
higher percentage of CSCs was found in primary tumors with distant metastases (66). 
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1.3 Development of CSC specific treatments 
 
The potential goal of a CSC-specific therapy is the eradication of all CSCs 
irrespective of their phenotypic heterogeneity. 
Remarkably defined signaling pathways, e.g. self-renewal regulation by Wnt in 
CRC might be shared by normal SCs and CSC (67). Therefore significant toxicity of 
specific treatments might be expectable (31). In addition, treatments directly affecting  
CSC might provide selective pressure, resulting in the emergence of resistant clones 
(31). 
Tumor microenvironment is a key factor modulating metabolism, tumor 
growth, progression and metastasis to distant sites, and ultimately poor prognosis (67-
69). Thus, the development of novel therapies targeting CSC might require an 
improved knowledge of mechanisms regulating SC and CSC interaction. Different 
approaches are currently being considered for the development of CSC-specific 
treatments. Surface markers representing potential targets for monoclonal antibodies 
are currently being evaluated. Alternatively the use of compounds inhibiting possibly 
with differential effectiveness, signaling pathways in common between SC and CSC, 
including Wnt/β-catenin, Hedgehog, Notch, Bmi-1, PTEN, telomerase, and efflux 
transporters, are also being investigated. 
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AIMS OF THE STUDY  
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The identification of markers identifying CSC is fundamental for the validation 
of the CSC paradigm and for the development of new CSC-specific drugs and novel 
therapeutic approach. 
Here we addressed: 
1) The prognostic relevance of the expression of CSC surface markers in CRC 
clinical specimens. 
2) The “in vivo” tumorigenicity of primary CRC derived cells, as related to their 
expression of putative CSC surface markers. 
3) The possibility of using cells derived from established CRC cell lines 
expressing CSC surface markers as CSC cellular model. 
4) The development of innovative culture models of potential relevance for 
the screening of anti CRC compounds. 
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During my doctoral studies I first addressed, in collaboration with the Institute 
of Pathology of Basel, we evaluated the prognostic significance of the expression of 
putative cancer stem cells markers on a large cohort of CRC. Then I evaluated the 
tumorigenicity of primary CRC specimens in immunodeficient mice based on the 
percentages of cells expressing putative CSCs markers in order to evaluate if a 
correlation engraftment potential could be postulated. 
 
Following these studies, I addressed the suitability of human established CRC 
cell lines for CSC specific drug testing. I established the expression of the putative CSC 
markers on the cell lines and then I compared the putative cancer stem cells isolated 
based on the expression of CSC markers with well-known stem cells and cancer stem 
cells features namely: spheroid formation ability, clonogenicity, enzyme and pump 
activity related to drug resistance, tumorigenicity, and drug resistance to drugs 
commonly used in CRC chemotherapy. 
Finally, considering the potential relevance of growth in spheroid architectures 
in CSC biology, I developed a three-dimensional culture system for established CRC cell 
lines. 
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3.1 Prognostic impact of the expression of putative cancer stem 
cell markers CD133, CD166, and CD44s in colorectal cancer 
Based on the original paper: 
Prognostic impact of the expression of putative cancer stem cell markers CD133, 
CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. 
Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, 
Terracciano L, Zlobec I. 
Br J Cancer. 2010 
 
Introduction 
Putative CSC populations have been identified in several types of solid tumors, 
on the basis of the expression of specific markers and of functional stem cell-like 
properties, including high clonogenicity, differentiation capacity, spheroid formation, 
and, critically, the ability to reproduce the original tumor on transplantation in 
immunodeficient mice (37-39, 70). 
Phenotypic characterization of CSC derived from colorectal cancers is still 
debated. Initial works indicated CD133 molecule as a reliable CSC marker in primary 
human colorectal cancers. Instead, Dalerba and colleagues identified CRC-SC in a 
subset of EpCAM positive cells co-expressing CD44 and CD166 (37-39). Subsequent 
studies have shown that in both mouse and human colorectal cancers the proposed 
markers are not restricted to rare cell subsets, but their expression can be detected in 
relatively large populations of tumor cells, irrespective of their tumorigenicity ((46) and 
Muraro et al, unpublished). 
CSCs have been suggested as the driving force behind tumor initiation, growth, 
and metastasis, with a potentially high clinical relevance. However, little and 
contradictory information is available in literature about the prognostic relevance 
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associated with the expression of putative CSC markers in CRC. Choi et al. reported no 
correlation between survival and high expression of CD133 and CD24 studying 523 
cases (71). Instead, Horst et al., Kojima et al., and Li et al. reported low to poor survival 
associated with high expression of CD133 in a cohort of 77, 189, and 104 cases, 
respectively (72-74). Contradictory findings have been reported about the association 
between the expression of CD44 and tumor progression, and, in particular, with the 
expression of its isoform CD44v6 (75-77). Membranous but not cytoplasmic expression 
of CD166 has been found to correlate with a shortened survival, in a study based on 
111 cases (23). A comprehensive analysis of the expression of multiple putative CSC 
markers in large groups of patients with detailed statistical analysis of the prognostic 
significance of the co-expression of multiple CSC markers within the same tumor is still 
missing. 
By using a tissue micro-array including 1420 primary colorectal cancers with full 
clinico-pathological data and follow-up we addressed expression and the prognostic 
significance of CD133, CD166, CD44s, and EpCAM expression in colorectal cancer. 
 
Materials and Methods 
Patients and clinico-pathological data 
Archival paraffin-embedded material from 1420 patients with primary, pre-
operatively untreated colorectal cancer were retrieved from multiple centers including 
the Institute of Pathology, University Hospital of Basel, Switzerland, the Institute of 
Clinical Pathology, Basel Switzerland and the Institute of Pathology, Stadtspital Triemli, 
Zürich, Switzerland. All histopathological information was systematically re-reviewed 
from the corresponding H&E slides including pT classification, pN classification, tumor 
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grade, histologic subtype, and the presence of vascular invasion. Tumor border 
configuration was diagnosed according to Jass et al. as “pushing /expanding” when 
there was a reasonably well-circumscribed margin at the invasive front and as 
“infiltrating” when no recognizable margin of growth and a streaming dissection 
between normal structures of the bowel wall was present (78). Clinical information 
was retrieved from patient records and included age, gender, tumor location, and 
disease-specific survival time. For patients diagnosed at the Institute for Pathology, 
Stadtspital Triemli, Zürich, information on local recurrence, (n=476), distant metastasis 
(n=489) and adjuvant therapy (n=478) was available. Patient characteristics are 
summarized in Table 2. The use of these materials in this study was approved by the 
local ethics committee. 
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Table 1 Summary of patient characteristics (n = 1420) 
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Tissue microarray and Immunohistochemistry 
Tumor specimens from all 1420 patients as well as 57 samples of normal 
colonic mucosa were included on a previously described tissue microarray (79). Tissue 
cylinders with a 0.6 mm diameter were punched from morphologically representative 
tissue areas of each “donor” tissue block and brought into one recipient paraffin block 
(3x2.5 cm) using a homemade semi-automated tissue arrayer. Immunohistochemistry 
was performed for protein markers CD133, CD44s, CD166. Detailed staining 
procedures have been described elsewhere (80). The following primary antibodies 
were used: anti-human CD133 (clone C24B9; 1:100; Cell Signaling), anti-human CD166 
(clone M0G/07; 1:200; Novocastra), and anti-human CD44s (clone DF1485; 1:50; 
Dako). Negative controls underwent the same protocol with the primary antibody 
omitted. Primary antibodies were omitted in slides serving as negative controls 
 
Evaluation of immunohistochemistry 
For CD133, CD166, and CD44s, only membranous staining was considered 
(Figure 7). Tissues were scored semi-quantitatively by evaluating the proportion of 
positive tumor cells over the total number of tumor cells (percentage of positive tumor 
cells per tissue microarray punch). Then, using receiver operating characteristic (ROC) 
curve analysis (81), appropriate cut-off scores for each marker were obtained. Positive 
staining in percentages of cells above or below the cut-off scores was classified as 
“overexpression” or “loss”, respectively. The reliability of the cut-off score was 
confirmed by 200 bootstrapped replications, a method which re-samples the data with 
replacement.  
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Figure 7 Colorectal cancer samples with membranous positivity and corresponding negative staining 
for CD133 (A and B), CD166 (C and D), and CD44s (E and F). 
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Tumor invasion assay 
The colorectal cancer cell lines LS180, SW480, and COLO205 were cultured in 
RPMI 1640 medium supplemented, with GlutaMAX, MEM NEAA, 10mM HEPES, 1mM 
sodium pyruvate, kanamycin sulphate, and 10% FCS (all the reagents were from Gibco, 
Paisley, UK). For invasion assays, cells were stained with APC-conjugated anti-CD44s 
and PE-conjugated anti-CD166 antibodies (BD Pharmingen, San Jose, CA, USA), and 
CD44+/CD166+ or CD44-/CD166- cell subsets were sorted by flow cytometry. Dead 
cells were excluded by DAPI staining. Purity of sorted cells was >97%. Unsorted tumor 
cells or sorted subsets were tested for invasiveness in a chemoinvasion assay (82). 
Briefly, tumor cells re-suspended in serum-free medium were seeded in transwell 
plates on uncoated or matrigel-coated membranes (8 mm pore size, BD Biocoat Tumor 
invasion assay, BD Biosciences, San Jose, CA, USA). Medium containing 5% FCS was 
seeded in the lower chambers and the cells were incubated at 371C for 20 h. Inserts 
were then removed and numbers of cells migrated into the lower chambers were 
quantified by CyQUANT Cell Proliferation Assay Kit (Invitrogen, Paisley, UK). 
Percentages of cell invasion were calculated according to the following formula: 
(relative fluorescent units (RFU) of cells invaded through matrigel-coated 
membranes/mean RFU of cells migrated through uncoated membranes) x100. 
 
Statistical Analysis 
Chi-Square tests were carried out for categorical endpoints. The product-limit 
method and log-rank or Wilcoxon tests were used to assess differences in survival 
time. The 5-year survival rates and 95% confidence intervals (CI) were obtained. For 
Cox multiple regression analysis, the assumption of proportional hazards was verified 
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prior to each analysis. Patient with missing clinico-pathological data or with non-
evaluable immunohistochemistry were excluded from the analysis. Hazard ratios (HR) 
and 95%CI were obtained to assess the prognostic effect of each protein marker on 
outcome. All tests were two-sided and p-values were considered statistically significant 
with p<0.05. 
 
Results 
Tissue microarray analysis: Normal mucosa versus colorectal cancer 
Mean percentage of cells expressing CD133 was <1% in normal mucosa and 
24.7% in CRC (p<0.001). CD44 and CD166, expression in normal tissue was detectable 
on average  in 4.3% and 41.3% of cells, respectively, and in 33.1% and 64.4% of cancer 
cells (p<0.001).  
In order to evaluate the prognostic significance of the expression of these 
markers receiver-operating curves (ROC) (81) were calculated. 
Based on the analysis of 1245 cases, a 5% cut-off score was defined for CD133 
expression. With this setting 616 cases (49.5%) displayed overexpression and 629 cases 
(50.5%) loss of expression. Neither condition showed a significant correlation with 
overall survival.  
Regarding CD166, cut-off score was established at 65%, based on the ROC 
analysis of 1274 cases. In 775 (60.8%) and 499 cases (39.2%), respectively, 
overexpression or loss of expression were detected.   
Interestingly, CD166 loss was associated to advanced pT (p=0.002), lymphatic 
metastases (p=0.004), and worse overall survival (p=0.015; Figure 3A). However, 
CD166 loss was not an independent prognostic factor in multivariable analysis 
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including age, T classification, N classification, vascular invasion, tumor border 
configuration and metastasis. 
Regarding CD44s (Table 2), the relevant cut-off score was set at 5% based on 
the analysis of 1261 individual specimens. In 607 cases (48.1%) we observed loss and in 
654 (51.9%) CD44 overexpression. Similarly to CD166, CD44 loss was associated with 
higher T stage (p=0.014) and lymphatic metastases (p=0.002). Most importantly 
survival rate was significantly lower (p=0.019) for patients bearing tumors with loss as 
compared to those bearing cancers overexpressing (Figure 8B). Again, however, the 
Table 2 Association of membranous CD166, and CD44s with clinico-pathological features in colorectal 
cancer patients. Abbreviation: CI = confidence interval; ROC = reveiver-operating characteristic. Cut 
off scores for overexpression derived from ROC curve analysis were 65% for CD166, and 5% for CD44s. 
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prognostic effect of CD44 loss was not independent, as shown by multivariable analysis 
taking into account age, TNM status, vascular invasion and tumor border 
configuration. 
  
Figure 8 Kaplan–Meier survival curves illustrating survival time differences in patients with (A) loss vs 
overexpression of membranous CD166, (B) loss vs overexpression of CD44s 
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Invasiveness of tumor cells differing in CD44 and CD166 expression 
Since CD44 and CD166 are adhesion molecules, we hypothesized that their loss 
might directly favor the invasiveness of tumor cells, possibly as a consequence of 
reduced adhesion. To address this issue in a controlled in vitro model, we investigated 
the invasive potential of CD44+/CD166+ or CD44-/CD166- cells derived from the 
human colorectal cancer cell lines, LS180, SW480 and COLO205. All three cell lines 
displayed a heterogeneous surface expression of CD44 and CD166 (Figure 9, left 
panels). However when CD44+/ CD166+ and CD44-/ CD166- cell subsets were sorted 
and evaluated for their invasive capacity, in all cases the double negative fractions 
exhibited significantly higher invasive potential than their positive counterparts (Figure 
9, right panels). These results suggest that absence of CD44 and CD166 molecules is 
directly associated to higher invasive capacity of tumor cells. 
 
  
Figure 9 The CD44-/CD166- tumor cells display higher invasive potential than CD44+/CD166+ cells. The 
CD44-/CD166- and CD44+/CD166+ cell subsets were sorted by flow cytometry, according to the gates 
depicted, from LS180, SW480, and COLO205 cell lines. Sorted subsets were tested in invasion assays. 
Percentages of cell invasion (mean values ± SD) are shown. Data are representative of six 
independent experiments. 
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Discussion 
We have evaluated the relationship between expression of proposed putative 
CSC markers and most clinically relevant features of colorectal cancer. Our findings 
suggest that, despite the increased expression of CD133, CD166, and CD44s, from 
normal to early colorectal cancer, their expression is not “per se” associated with 
unfavorable prognosis. In contrast, it is the overall decreased membranous expression 
of CD166, and CD44s, which is linked to tumor progression and an aggressive tumor 
phenotype, a result confirmed for CD44s and CD166, using three established colorectal 
cancer cell lines. 
CD44 has long been thought of as a marker of tumor invasiveness and 
metastasis and has also recently been described as a putative colorectal CSC marker 
(39). Early works investigating the CD44s gene reported a poorer survival in patients 
with increased expression levels of the specific gene or protein (76). However, more 
recent results suggest either no role for CD44s or a worse clinical outcome associated 
with loss of protein expression (71, 83). As already shown by others (77), we also 
observed an increasing expression of CD44s from normal to tumor tissue. Notably, loss 
of membranous CD44v6 expression has been shown to be linked to a highly aggressive 
tumor phenotype (79). In this study, we found that loss of CD44s expression is linked 
to a significantly worse clinical outcome in univariate but not in multivariable analysis 
suggesting that the findings concerning survival time may be confounded by other 
relevant prognostic factors.  
Regarding the prognostic impact of CD166 in colorectal cancer an increasing 
expression of CD166 from normal to tumor tissue (23), and also an age-dependent 
correlation between the increase of CD44 and CD166 expression and the numbers of 
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polyps has been reported (84). We confirmed the previous findings but, in contrast, we 
observed a significant adverse effect of loss, rather than increase, of membranous 
CD166 expression on clinical outcome. A similar association between decreased 
membranous CD166 staining and poorer prognosis was previously reported in other 
tumor types, including ovarian and prostate cancer (85, 86). 
The prognostic significance of CD133 expression in primary CRC has been 
previously evaluated in a few studies. Either no correlation (73) or a significant 
negative association (49, 71-74) between increased CD133 expression and clinical 
outcome has been found in studies including limited numbers of cases (77 (72), 189 
(73), and 104 (74) cases). However, recent study, including a larger group of cases 
(n=523), reported lack of correlation between CD133 expression and patient survival 
(71). In line with the latter findings, we also did not observe any significant correlation 
between CD133 and clinical outcome. Thus, CD133 expression does not appear to be 
per se predictive of unfavorable clinical outcome. 
Several reasons for these discrepancies can be hypothesized including 
differences in sample size (power for detecting prognostic differences), methodology 
(tissue microarray versus whole tissue sections) and certainly the choice of cut-off 
scores for the definition of positive staining or staining intensity.  
Since loss of expression of CD44 and CD166 by immunohistochemistry 
correlated with worse prognosis, we further evaluated the in vitro the invasive 
capacity of CD44-/CD166- and CD44+/CD166+ cells sorted from three established 
human CRC cell lines. Indeed, in all cases a highly significant increase of the invasive 
potential was noted for the CD44-/CD166- fraction. Our in vitro findings strongly 
suggest that CD44 and CD166 expression may limit tumor cell spreading in surrounding 
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tissues, thus underlining the hypothesis that loss of expression of these markers, 
rather than their over-expression, is associated with a more aggressive tumor 
phenotype.  
To our knowledge, this is the first systematic assessment of the prognostic 
value of CD133, CD166, and CD44 in colorectal tumors evaluated on a large number of 
cases. Our findings indicate that expression of CSC markers is not per se predictive of 
poor clinical outcome. Loss of expression of CD166, and CD44s is rather linked to an 
aggressive tumor phenotype, and, particularly, to the presence of an infiltrating tumor 
margin which may implicate these proteins in events occurring at the invasive tumor 
front. 
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3.2 Higher percentage of CRC-SCs in primary CRC does not 
correlate with higher engraftment rates in immunodeficient 
mice  
 
 
Introduction 
Human tumor biology has long been studied in experimental xenogeneic colon 
cancer models, by injecting cell lines, or cell suspensions or fragments of primary 
tumors into immunocompromised mice.  
The emerging concept of CSCs represents an innovative model with the 
potential to unravel new approaches for both drug discovery and preclinical screening. 
The gold standard for the identification of CSCs is represented by their in-vivo tumor 
formation capacity in immunodeficient mice recapitulating all the more differentiated 
cell populations detectable in primary tumors. Furthermore CSC should be serially re-
transplantable consistent with a self-renewal potential (87).  
Xenografts are usually implanted into subcutaneous tissue, a site easily 
accessible for both graft procedure and observation of tumor growth. Despite their 
ectopic location, CSCs have been shown to display a distinctive ability to generate 
heterogeneous tumors with histological patterns similar to those detectable in clinical 
specimens. 
The study of CSCs in solid cancers presents technical hurdles related to tissue 
dissociation, separation of cellular subpopulations, and a poor knowledge of 
membrane markers. The extensive manipulation required by the isolation of cells 
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expressing CSC markers from primary tumors could affect their tumorigenic potential. 
Our approach was to evaluate the tumorigenic potential of CRC cells expressing 
putative CSC markers without sorting them from the original primary tumor derived 
cell suspensions but inoculating the entire heterogeneous population subcutaneously 
into the mouse flank, in order to investigate if samples with different expression of 
putative CSC markers may have different capacity to engraft in mice. Our data indicate 
that there is no correlation between percentages of cells expressing of CSC markers in 
tumor cell suspensions and their tumorigenic capacity in different immunodeficient 
recipient models. 
 
Materials and Methods 
Digestion of human tumor specimens 
Tumor cells suspension were derived from freshly excised CRC samples, 
obtained from consenting patients undergoing surgical treatment at Basel University 
Hospital, Kantosspital St.Gallen and Ospedale Civico di Lugano.  Tissues were 
enzymatically digested in serum-free DMEM (GIBCO), supplemented with Collagenase 
IV (1mg/ml) and DNAse I (50 mg/ml, both from Sigma-Aldrich), and a cocktail of 
antibiotics, including Kanamycin (GIBCO), Amphotericin B (Sigma-Aldrich), 
Metronidazol (200mg/ml, Sigma-Aldrich) and Cefuroxim (6mg/ml, Sigma-Aldrich). After 
digestion, tissue explants were ground inside a 100 μm sterile cell filter with the blunt 
end of a Luer syringe while continually rinsing with cell medium. Once most of the cells 
were collected, the mixture was filtered again through a 70 µm sterile cell filter and 
centrifuged for 5 min at 1500 rpm. The supernatant was removed and cells were 
resuspended in 1 mL of medium and counted. 
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Tumor transplantation 
In vivo experiments were approved by the Basel Cantonal Veterinary Office. 
Eight–ten week old NOD/SCID (NS) and NOD/SCID IL-2 receptor γ chain (NSG) deficient 
mice, initially obtained from Charles River Laboratories (Germany), were bred and 
maintained under specific pathogen free conditions in the animal facility of the 
Department of Biomedicine of the University of Basel. Eight to ten week old mice were 
used for xenografting experiments.  
Freshly isolated primary tumor cells (500.000) prepared in a 1:1 mixture of PBS 
and Growth Factor Reduced BD Matrigel Matrix (BD Biosciences) were injected in the 
left flank of recipient mice. Tumor development was monitored by palpation. Time to 
onset of a palpable tumor was recorded and the tumor size was measured weekly by a 
dial caliper. Tumor volumes were calculated according to the formula (length x 
width2)/2. Mice were sacrificed when tumors reached a maximum diameter of 10 mm. 
 
Flow cytometric analysis 
Surface phenotype of freshly isolated primary tumor cells was determined by 
flow cytometry. The following antibodies were used: phycoerythrin- (PE) or 
allophycocyanin- (APC) labeled anti-CD133 (clone AC133/1, Miltenyi Biotec, Bergish, 
Gladbach, Germany), PE-labeled anti-CD166 (clone 3A6, BD Biosciences, San Josè, CA), 
fluorescein isothiocyanate- (FITC) , APC- or APC-H7-labeled anti-CD44 (clone G44-26, 
BD Biosciences), FITC- or PE-labeled anti-CD24 (clone ML5, BD Biosciences). Propidium 
iodide (PI, 0.5 µg/ml) was added to the samples prior to analysis. Relative fluorescence 
intensities were measured using a BD FACS Calibur flow cytometer (BD Biosciences), or 
a CyAn ADP Analyzer (Beckman Coulter, Krefeld, Germany) following exclusion of dead 
- 50 - 
 
cells based on PI incorporation. Analysis was performed using FlowJo software (Tree 
Star, Portland, OR). 
 
Statistical Analysis 
Statistical analysis was performed by 2-tailed Student’s t-test using the 
GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA). P-values ≤0.05 were 
considered significant. 
 
Results 
CRC samples phenotype 
We analyzed the expression of putative CRC-SC markers CD133, CD44, CD166, 
and CD24, and their combinations within EpCAM positive population in all human CRC 
samples processed and also in the corresponding healthy mucosa (n = 51). We found 
that expression was significantly higher in the tumor as compared to the autologous 
corresponding healthy mucosa for all markers alone (CD133 p<0.0001; CD44=0.0004; 
CD166 p=0.0015; CD24 p=0.004) and in combination (CD166/CD44 p=0.0212; 
CD133/CD44 p=0.0121) (Figure 10a). Notably, we observed that several tumor samples 
expressed the putative CSC markers at high extents and, in general a high 
heterogeneity was observed among the specimens analyzed (CD133 range 0.12-
77.12%; CD44 range 0,48-70.64%; CD166 range 0.18-41.12%; CD24 range 7.66-98.58%) 
(Figure 10A and Table 3A and 3B). 
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Table 3A Summary of phenotypical characterization of tumorigenic CRC samples analyzed. 
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Table 3B Summary of phenotypical characterization of non tumorigenic CRC samples analyzed. 
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Tumorigenic potential of CRC-derived cell suspension 
We then analyzed the correlation occuring between percentages of cells 
expressing CSC markers within the primary tumor derived cell suspensions and their 
relative tumorigenic capacity in two immunodeficient mouse models (NS and NSG) 
which were previously suggested to be characterized by differential “tumor take” 
capacity (37-39). Mouse engraftment was successful for 24 out of 51 human tumor 
specimens tested.  Their capacity to engraft did not correlate with the percentages of 
cells bearing CSC markers within the epithelial fraction of the injected CRC derived cell 
suspensions tested (Figure 10B). Importantly, even tumor specimens highly expressing 
CSCs markers failed to efficiently engraft. 
Furthermore, comparing the tumorigenic potential in two differentially 
immunodeficient mouse strains we did not observe significantly different engraftment 
capacity (NS 14/28; NSG 10/23) (table 3). 
Figure 10 (A) Putative CSC marker expression in healthy mucosa as compared with corresponding 
tumor tissues. Percentage are related to the EpCAM positive cell fraction. (B) Engraftment capacity in 
relation to the expression of CSC markers in tumor tissue. 
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Discussion 
Subcutaneous engraftment in immunodeficient mice is a widely used technic 
for the expansion of primary tumor cells possibly maintaining biological and 
histopathological features of original tissues (88). 
According to the CSC model, only a subset of tumor cells has the capacity to 
sustain tumor growth and to reproduce the cellular heterogeneity typically 
characterizing clinical cancer specimens. It has been demonstrated that only the cells 
expressing CSC surface markers are able, once isolated and subcutaneously injected 
into immunodeficient recipient, to recapitulate the original heterogeneity of cancer 
cells of the tissue of origin. 
In CRC it has been suggested that cells expressing CD133 (37, 38), or both 
CD166 and CD44 (39), sorted from digested primary tumor tissue, are capable to 
serially engraft in immunodeficient mice. 
Our results show that all putative CSC markers are expressed to significantly 
higher extents in the tumor tissue as compare to the corresponding, autologous 
healthy mucosa. Most importantly, there is no correlation between percentages of 
EpCAM positive expressing defined CSC markers in primary tumor derived cell 
suspensions and their engraftment capacity. For CD44 and CD166 only 4/21 and 4/23 
specimens, respectively, with more than 10% positive cells developed tumors. For 
CD133 and CD24 only 9/23 and 4/6 samples expressing markers in more than 10% of 
cells successfully engrafted.  
Thus, CSC marker expression is not restricted to a small subset of cells within 
the tumor mass but it might rather be patient dependent. 
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Furthermore, samples characterized by high percentages of CSC markers 
expressing cells (CD133 range 0.12-77.12%; CD44 range 1.16-70.64%; CD166 range 
0.59-41.12%; CD24 range 7.66-98.58%) (Figure 10A and Table 3) were unable to 
generate detectable tumor mass. These results contrast with the previously reported 
by Ricci-Vitiani, O’Brien, and Dalerba (37-39).  
Our findings question the consistency of xenografting as “gold standard” assay 
for the identification and phenotypic characterization of CSCs or the validity of the 
proposed markers for the isolation of CRC-SCs. 
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3.3 CRC CSC Markers in human established CRC Cell Lines
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Supplementary Figure 1 Phenotypic profiles of CRC cell lines cultured in the presence or absence of 
serum. CRC cell lines were cultured up to 10 days in serum containing or in SF medium and stained 
with APC-labeled anti-CD133, PE-labeled anti-CD166, APC-H7-labeled anti-CD44, and FITC-labeled 
anti-CD24 antibodies.  Histograms represent the fluorescence intensity of the indicated marker in cells 
cultured in serum containing (solid red line) or in SF medium (solid blue line) overlaid to 
corresponding isotype controls (tinted red histogram and dashed blue line, respectively). 
- 70 - 
 
Supplementary Figure 2 Definition of gates used for cell sorting 
CD133+ and CD133- cells were sorted from CACO2, HCT116, COLO205, and HT29 cell lines following 
staining with PE-labeled anti-CD133 antibodies. CD166+CD44+ and CD166-CD44- cells were isolated 
from LS180, SW480, COLO205, and SW620 cell lines, following staining with PE-labeled anti-CD166 and 
APC-labeled anti-CD44 antibodies. CD24+CD44+ and CD24-CD44+ cells were sorted from LS180, 
SW480, DLD1, and SW620 cell lines following staining with PE-labeled anti-CD24 and APC-labeled anti-
CD44 antibodies. Cell subsets were gated as depicted, after exclusion of dead cells, based on 7-AAD 
incorporation. 
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Supplementary Figure 3 ALDH-1 activity in CRC cell lines does not correlate with the expression of 
putative CSC markers. A. CRC cell lines were stained with the Aldefluor Kit assay. Representative dot 
plots illustrating ALDH-1 activity obtained upon staining of CRC cells in the absence, or presence of 
DEAB are shown. B. Aldefluor-stained CRC cells were counterstained with CD133-, CD166-, CD44-, and 
CD24-specific antibodies. Percentages of CD133+, CD166+CD44+, or CD24+CD44+ cells within unsorted 
(Uns), Aldefluor+ (Ald+) or Aldefluor- (Ald-) cells were assessed. Average frequencies ± SD from two 
experiments are reported. 
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Supplementary Figure 4 SPs in CRC cells lines do not preferentially express CSC markers. A. CRC cell 
lines were stained with Hoechst 33342 and percentages of SP were gated in comparison to samples 
treated with Verapamil. B. Hoechst-stained cells were counterstained with CD133-, CD166-, CD44-, 
and CD24-specific antibodies. Frequencies of CD133+, CD166+CD44+ or CD24+CD44+ cells within 
unsorted (Uns), SP, or non-SP cells were assessed. Average frequencies ± SD from two experiments 
are reported. 
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Supplementary Figure 5 Tumor growth kinetics upon injection of putative CSCs in immunodeficient 
mice. NOD/SCID mice were injected subcutaneously with: CD133+, CD133-, or unsorted cells from the 
HCT116 cell line (104 cells/mouse); CD166+CD44+, CD166-CD44-, or unsorted cells from the LS180 cell 
line (104 cells/mouse); CD24+CD44+, CD24-CD44+, or unsorted cells from the LS180 cell line (103 
cells/mouse). Tumor volume was assessed over time. 
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Introduction 
Pre-screening of novel potential anti-cancer agents is conventionally conducted 
on established cancer cell lines from the US National Cancer Institute (NCI) 60 panel, a 
collection of 60 tumor cell lines representing nine distinct human tumor types (89). 
These cells growing in two-dimensional (2D) monolayers are easy to propagate and 
amenable to high throughput studies. However, it is well known that these cells 
growing in 2D inadequately reflect the genetic make-up of the cancer cells in human 
disease, possibly because of missing features of the three-dimensional (3D) in vivo 
microenvironment that has a huge impact on cell proliferation, differentiation, 
migration, and intracellular signal transduction (68, 90-94). This might represent the 
background for the high attrition rates of compounds that are selected during pre-
clinical studies. Therefore the pharmaceutical industry is highly interested in models 
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that increase the efficacy of pre-screening to reduce the high failure-rate in drug 
development. Although 3D in vitro models are known since more than thirty years 
(68), only recent work has highlighted the need for better 3D models that may bridge 
the gap between conventional 2D models and in vivo studies (95).  
The multicellular tumor spheroid (MCTS) model is one of the  best established 
3D culture methods and it is currently being tested for drug screening purposes (96). 
MCTSs are cellular aggregates that resemble the microenvironmental condition of 
small avascular tumor regions and micrometastases (68). MCTS may be cultured 
exploiting the hanging-drop method described by Kelm et al (96) based on the capacity 
of cells to adhere to each other without artificial scaffolds.  
Most solid tumors develop hypoxic regions which may determine dramatic 
changes in tumor cell gene expression (97). Tumors with hypoxic areas are known to 
display a more aggressive tumor phenotype and tumor cells in hypoxic areas are also 
more resistant to chemo- and radio-therapies due to direct and indirect effects of 
hypoxia (91, 98, 99). Furthermore, hypoxia seems also to be associated with the 
generation or expansion of tumor-initiating cells or cancer stem cells (CSC) (100). 
Therefore, MCTS may represent a good tool to study cancer stem cell biology and the 
best in the development of CSC-specific drugs.  
Similar to in vivo tumors, with increasing size, hypoxia and apoptosis/necrosis 
occur within MCTS due to oxygen and nutrient gradients (101). The effects of these 
phenomena on gene expression profiles of human colorectal cancer (CRC) MCTS at 
different growth stages have not been elucidated so far. 
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This study presents a straightforward method to obtain human CRC-MCTSs of 
different sizes resembling specific growth stages characterized by the presence or 
absence of hypoxic and/or apoptotic/necrotic cores.  
In order to obtain insights into similarities and differences between tumor cells 
growing in physically different microenviroments, here we analyzed gene expression 
profiles of CRC cells cultured in standard 2D conditions, as MCTS, or growing in a in-
vivo environments as xenograft in immunodeficient mice. 
The comparison of the gene expression profiles of MCTS at different stages 
with CRC cells cultured on monolayer or xenografts showed that the presence of both 
hypoxic and necrotic cores are essential to adequately mimic in vivo conditions. 
 
Material and Methods 
Cell cultures 
Authenticated human established colorectal cancer cell lines HCT116 and HT-29 
were purchased from American Type Culture Collection (ATCC, Manassas, VA). HCT116 
cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (FBS),  
GlutaMAX-I, Non Essential Amino Acids (NEAA), 100 mM sodium pyruvate, 10 mM 
HEPES (all from Gibco), and 50 μM 2-Mercaptoethanol (Sigma). HT-29 was maintained 
in McCoy’s 5A (Sigma) supplemented with 10% FBS and GlutaMAX-I. Both media were 
also supplemented with kanamycin sulphate (Gibco). Cells were cultured at 37°C with 
5% CO2. The absence of mycoplasma contamination in cells was verified by PCR testing 
prior to investigation. 
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Generation of MCTS 
MCTS were formed by the hanging drop method as described by Kelm JM and 
collegues (96) using the 96-well GravityPlus plates (Insphero AG, Zurich, Switzerland), 
where each well consists of a hourglass-like structure open on both sides. The shape of 
the wells allows the creation of hanging-drops in the lower part and enables the 
change of the medium through the upper part, without modifying the MCTS structure. 
Briefly, cells were seeded as a single cell suspension of 40 μl per well by top-loading. 
Medium change was performed replacing twice half of the old medium with fresh 
medium, every three-four days. All steps were performed using an automatic 
multichannel pipette at a flow rate of 10 μl/s (Viaflo, Integra Biosciences, Zizers, 
Switzerland). After seeding the cell plates were cultured at 37°C with 5% CO2 for 3–4 
days to allow cell assembly for gravity-enforced and the formation of the MCTS. 
 
Growth kinetics analysis 
MCTS growth kinetic was examined at different time-points using an inverted 
phase contrast microscope (Nikon Eclipse TS100, Nikon Co.) equipped with a digital 
camera (Nikon Digital Sight DS-2MBWc, Nikon Co.). Five pictures for each time-point 
were acquired and MCTSs diameters were measured (Image-Pro Plus v4.5.1, Media 
Cybernetics). 
 
Xenograft cultures 
In vivo experiments were approved by the Basel Cantonal Veterinary Office. 
NOD/SCID mice, initially obtained by Charles River Laboratories (Sulzfeld, Germany), 
were bred and maintained under specific pathogen free conditions in the animal 
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facility of the Basel University Hospital. Eight to ten week old mice were used for 
experiments. For both cell lines one hundred thousand cells were re-suspended in a 
1:1 mixture of PBS and BD Matrigel Matrix Growth Factor Reduced (BD Biosciences) 
and inoculated subcutaneously into the flank of recipient mice. Tumor formation was 
monitored weekly by palpation and caliper measurements. Mice were sacrificed when 
tumors reached a maximum diameter of 10 mm. Samples from all mice were frozen in 
RNA Later (Sigma-Aldrich) and embedded in Optimal Cutting Temperature compound 
(OCT) (CellPath Ltd, UK) for subsequent gene expression evaluation and histological 
examination after cryocutting, respectively. The remaining tissues were enzymatically 
digested and the presence of tumor cells was assessed by flow cytometry upon 
staining with human EpCAM-specific antibodies (clone EBA-1, BD Bioscience). 
 
Spheroid fixation, cryosection and H&E staining 
After harvesting, MCTS were fixed in cold methanol for 10 minutes at -20°C, 
washed in PBS, and then transferred to molds, embedded in OCT, and stored at -80°C 
until sectioning. Serial frozen sections were cut at 10 μm with a cryostat, and mounted 
onto Superfrost Plus microscope glass slides (Menzel-Glaeser, Braunschweig, 
Germany). Sections were stored at -20°C until further use. Hematoxylin and eosin 
(H&E) staining of cryostat-sectioned slides was performed in an automatic staining 
workstation Tissue Stainer COT 20 (Medite GmbH, Burgdorf, Germany) with standard 
procedures. 
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Immunostaining 
For immunofluorescence staining, sections were blocked with 2% goat serum 
diluted in PBS containing 0.3% Triton X-100 for one hour at room temperature (RT) and 
then incubated with either rabbit monoclonal anti-Ki67 (Abcam, 1:200), rabbit 
monoclonal anti-cleaved caspase 3 (Cell Signaling Technology, 1:200), or mouse 
monoclonal anti-EBP50 (BD Biosciences, 1:50) for one hour at 37° C. Slides were 
washed with PBS and then incubated for one hour at RT with goat anti-mouse or anti-
rabbit Alexa Fluor 488- or 546-conjugated antibodies (Invitrogen, 1:800). During the 
last ten minutes of incubation DAPI (Invitrogen, 1:100) was added. Sections were 
analyzed either on a confocal laser scanning microscope (Zeiss LSM-710 system, Carl 
Zeiss Microimaging GmbH) or on a fluorescence microscope (Olympus BX61, Olympus 
Inc.).  
To detect hypoxia, immunohistochemical staining with the monoclonal 
antibody hypoxia-inducible factor 1, variant alpha (HIF1α) (Abcam, 1:25) was 
performed. After adding the blocking solution (1% goat serum diluted in PBS) for 30 
minutes to prevent unspecific binding, the sections were incubated with HIF1α 
antibody for 16 hours at 4° C in a dark wet chamber. Sections were washed with 
double distilled water and incubated for 30 minutes at RT with the secondary antibody 
conjugated to alkaline phosphatase (AP Histofine Simplestain M). The primary-
secondary complex was then detected by enzymatic reaction by adding an appropriate 
chromogenic substrate (Histofine 415161F, New Fuchsin Substrate Kit) for 5 minutes at 
RT. After blocking the reaction by immersing the slides in tap water, nuclear staining 
was performed using hematoxylin staining. Sections were analyzed on a fluorescence 
microscope (Olympus BX61, Olympus Inc.). 
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Real-time RT-PCR 
Total RNA isolation was performed using the Nucleospin RNA isolation kit 
(Macherey-Nagel GmbH & Co.) according to the manufacturer's protocol. RNA 
concentration and quality were evaluated using Nanodrop ND-1000 
spectrophotometer (Thermo Scientific Inc.). Reverse transcription was performed 
using the M-MLV-RT enzyme kit (Invitrogen, Basel, Switzerland), following the 
manufacturer’s recommendation, and cDNAs were then stored at -20°C for further 
use.  
A TaqMan Custom Array micro fluidic card (Applied Biosystems Inc.) was 
designed to study a panel of 94 genes of interest (Supplementary Table 1). The cards 
were run on a 7900HT thermal cycler (Applied Biosystems Inc.) according to 
manufacturer’s guideline. The comparative Ct method was used to quantify the 
relative gene expression levels, upon normalization against the expression of the 18S 
housekeeping gene as reference. Each sample was assessed in duplicate and 
experiments were repeated twice. Data were analyzed using Spotfire software (TIBCO 
Software, Somerville, Massachusetts, US) to generate the heat map and cluster plot 
analysis. 
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Results 
MCTS formation and growth kinetics 
As first stem, we tested the growth kinetics of MCTSs generated by different 
numbers of cells (100, 500, and 1000 cells per well), in order to identify the right 
starting condition to obtain small and compact MCTSs within 3 or 4 days. Optimal 
initial cell density was defined at 100 tumor cells per hanging drop both for HT29 and 
HCT116 (Figure 11 and data not shown).  
 
Figure 11 MCTS were generated from the HT29 CRC cell line by the hanging drop method. Cultures 
were performed in suspension using InSphero GravityPlus plates. To determine the optimal initial 
cell density, titrated tumor cell numbers per drop were seeded and MCTS growth kinetic was 
monitored. (A) MCTS growth over time. Optimal initial cell density was defined at 100 tumor cells 
per hanging drop. Day 6, 9, and 14 were defined as optimal timepoints for different MCTS stages. (B) 
MCTS proliferation; cell numbers obtained at different stages. (C) MCTS morphology over time. Scale 
bars represent 100 µm. 
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Definition of MCTS maturation stages  
MCTSs were analyzed at different time-points aiming at the identification of 
three growth stages, characterized by presence of only normoxic cells (stage1), a 
hypoxic area in the inner part of the MCTS (stage2), and hypoxic and 
apoptotic/necrotic cores (stage3). In previous studies it has been reported that a 
hypoxic core begins to be formed in spheroids larger than 200 µm and that a necrotic 
core is detectable in MCTSs larger than 500 µm (101). Based on these findings we 
defined our time-points to obtain within 6-7 days a diameter size <200 µm for the 
stage 1, within 9-10 days a diameter of 300-350 µm for the stage 2 and within 14-15 
days a diameter size >500 µm for the stage 3, respectively for HT29 and HCT116 cells 
(Figure 11A and data not shown). We confirmed the presence of a hypoxic area within 
the MCTSs stage 2 by the detection of hypoxia-inducible factor 1a (HIF1a) positive 
staining (Figure 12, E-L). The presence of apoptotic/necrotic cells was assessed by 
cleaved caspase3 (cC3) staining and ethidium homodimer incorporation (Figure 12, M-
P and Supplementary Figure 1). We observed only few apoptotic/necrotic cells in the 
first two stages. Instead, in stage 3, we detected an apoptotic/necrotic core. By 
staining with Ki-67 MCTS we could show a highly compact and organized cell growth in 
outer layers at any maturation stage (Figure 12, Q-T). 
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Figure 12 To detect hypoxic and necrotic inner cores and proliferating cells we performed immuno-
fluorescence and immunohistochemistry on frozen sections with hypoxia-inducible factor 1 alpha 
(HIF-1α), cleaved caspase-3 (CC-3), and Ki-67 specific antibodies, respectively. 
Stage 1 (MCTS diameter size < 200 µm) was defined by the absence of hypoxia/necrosis (E, I, M), stage 
2 (300-350 µm) was characterized by the presence of hypoxic, but not necrotic cores (F, J, N) and stage 
3 (> 500 µm) was identified by the presence of both hypoxic and necrotic cores (G, K, O). At all 
maturation stages actively proliferating cells were mainly detected within the outer layers of MCTS 
(Q-S). Xenograft cultures of HT29 were obtained (HT29 cells were injected in NOD/SCID mice) and 
frozen sections were stained in the same manner as above (D, H, L, P, T) showing all features of stage 
3 MCTS. Scale bars represent 100 µm. 
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Figure 13 Cells obtained from 2D culture (2D), MCTS at first growth stage (3D 1S), second growth stage 
(3D 2S), third growth stage (3D 3S), and as xenograft (Xeno) were analysed using real-time 
quantitative PCR. Expression of each gene was normalized to that of 18S mRNA and is presented as 
2−ΔCt. The relative mRNA expression levels are shown as means ± SD (n=2) 
Differential gene expression patterns 
We then analyzed the gene expression profile of a panel of 94 genes related to 
tumor progression, metastatic behavior, and drug resistance in five different condition 
of growth namely: two-dimensional (2D) culture, stages 1, 2, and 3 of MCTS 
development (3D1, 3D2, and 3D3), and xenografted tumor cell (Xeno). For several 
genes we found a progressive up-regulation moving from 2D to 3D up tp xenograft. In 
particular this was conspicuously evident for P53, TRAIL, FAS, BAX, EpCAM, KRT20, 
CD133, CD44, and CD24 genes (Figure 13).  
In order to highlight the difference between 2D- and 3D-culture we calculated 
the ratio between the gene expression found in 3D   against that of the 2D. Comparing 
the three growth stages and the in-vivo condition, we observed a higher correlation 
between 3D stage-3 and the in-vivo condition. On the other hand the 3D stage-1 
profile presented a remarkable similarity with the gene expression pattern detectable 
in cells cultured in 2D (Figure 14). 
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Figure 14 MCTS at different 
maturation stages and xenograft 
cultures were assessed for the 
expression of 94 genes related to 
tumor progression, metastatic 
behavior, and drug resistance in 
comparison to conventional 2D 
cultures, by real time PCR, in 
comparison to conventional 2D 
cultures. Heatmap (mean of two 
experiments, fold change as 
compared to 2D). In preliminary 
experiments, the expression of a 
panel of genes, including KRAS, 
p53, CEACAM5, and the putative 
cancer stem cell markers CD133, 
CD44, CD166, and CD24 was found 
to be progressively upregulated 
from  stage 1 MCTS, as compared 
to 2D cultures.  
Similarly, upregulated gene 
expression patterns were also 
detectable in “in vivo” xenografted 
tumors. 
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Discussion 
Two-dimensional monolayer cultures are traditionally used to investigate 
cancer biology and develop novel treatments but they inadequately reproduce the 
pathophysiology of solid tumors (91, 102). Indeed 2D-culture of cell lines is simple, 
convenient, and amenable of high-throughput studies. However, it lacks the 3D 
structural architecture usually preserved in organ cultures (103). On the other hand, 
organ cultures may also be problematic, due to poor standardization and poor ability 
to grow in vitro.   
Solid tumors often display hypoxic and necrotic areas. Furthermore, the 
presence of cells expressing stem cell characteristics, slow proliferation and barriers to 
drug diffusion contribute to drug resistance. These characteristics are not adequately 
reflected by monolayer cell cultures (102). Unlike monolayer culture, 3D-culture 
models capture the complexity of solid tumors and they might thus represent excellent 
tools for the development of novel in vitro assays and models of neoplastic cell culture 
with high potential clinical relevance. Indeed, cells cultured in 3D conditions have been 
shown to be endowed with specific characteristics, including resistance to apoptosis, 
and chemo- and radio-therapy, features closely matching those of ‘‘in vivo’’ tumors 
(68, 93, 97). On the other hand, MCTS 3D culture systems can easily be manipulated 
and exposed to specific treatments, at difference with in vivo xenografts (105). 
 
Our experiments were performed using a 96-well GravityPlus plates from 
InSphero AG allowing easy handling of the hanging-drops cell culture technic and the 
possibility to make medium changes when needed (performed every 3 to 4 days) 
without perturbing the spheroid formation and growth. Thus, it was possible to 
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perform long-term MCTS culture. We could show that HT29 MCTS volume increased as 
a function of time in culture (Figure 7a) displaying the typical pattern of a Gompertz 
growth curve, a mathematical description of tumor and also spheroid growth kinetics 
characterized by an initial exponential increase in diameter followed by a growth 
deceleration phase (105-107).  
HT29 cells generate, after six and nine days of culture, MCTSs with a diameter 
around 200 μm and 300 μm, respectively. By staining for HIF-1a, we demonstrated that 
a formation of a hypoxia areas occurs in MCTS with a size over 200 µm, similar to 
tumors in vivo, as also reported by Hirshhauser et al. (101). 
The characterization of the third growth stage has been performed by testing 
the expression of cleaved caspase 3 (cC3) that is well known to be associated to 
apoptotic and necrotic events (108, 109). Apart for sporadic positive signals, both first 
and second growth stages were negative for cC3 (Figure 12, M and N, respectively). 
Instead, MCTS with a diameter >500 μm showed an apoptotic/necrotic core 
characterized by a cC3-positivity localized in the inner core of the spheroid structure 
(Figure 8, O). To confirm the cC3 staining data, we performed a two-color fluorescence 
cell viability assay that is based on the simultaneous determination of live and dead 
cells measuring intracellular esterase activity and plasma membrane integrity. We 
stained entire MCTSs showing live green-colored cells and eventually dead red-colored 
cells. Only in the third stage of growth a distinct accumulation of red signal in the 
spheroids central core was visible (Supplementary Figure 1). 
Due to cell proliferation, the MCTSs increase in diameter over the time, 
generating concentration gradients of nutrients, oxygen, and catabolites. These 
transport phenomena have also been described in avascular tumors where the 
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formation of necrotic areas occurs (91, 92). By staining with Ki-67, we observed that in 
the first stage proliferating cells are numerous and spread within the MCTS whereas in 
the second stage they are mainly localized in the outer layer of the spheroid. Instead, 
in the third stage is possible to detect proliferating cells only in a compact ring 
localized in the outer MCTS layer. The inner core of the MSCTs is characterized by the 
presence of live quiescent cells or dying cells.   
It has been reported that proliferation and functional features as well as the 
microenvironmental conditions inherent with the 3D cell-to-cell and cell-to-matrix 
interactions can affect gene and protein expression, and distribution and penetration 
of soluble factors including potentially therapeutic compounds (101). A number of 
comparative studies show that numerous genes are differentially expressed in cells 
cultured as MCTS versus monolayers (110-113). However, most of them were 
conducted on spheroids with a size of 300/350 μm and then possibly characterized by 
only the presence of hypoxia. To the best of our knowledge, no comparative study 
focusing the attention on the gene expression profiles of different spheroid maturation 
stages has been reported so far.  
In this study we compared gene expression profiles of HT29 cells cultured as 
MCTS at three different stages with cells culture in 2D monolayers or engrafted in vivo 
upon xenografting in mice. We observed that the presence of both necrotic and 
hypoxic cores significantly impacts on gene expression profiles, resulting in patterns 
closely, resembling the in vivo situation as simulated by the xenograft. On the other 
side, MCTS with diameters <200 µm showed a gene expression profiles analogous to 
monolayer culture.  
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Hypoxic microenvironment has been shown to induce increased expression of 
p53 in solid tumors (92, 114). It has been observed that CRC cells respond to hypoxia 
by activating p53 and the apoptotic pathway through the HIF response element (HRE). 
HRE, in turn, activates the transcription initiation of fas gene causing the up-regulation 
of Fas/CD95 death receptor. Our data demonstrate an increasing expression of p53 
and Fas through the three stages of MCTS maturation, especially evident at the third 
stage of maturation, as also confirmed by the parallel up-regulation of other apoptotic 
markers including TRAIL and BAX. 
The analysis of the expression of genes encoding putative cancer stem cell 
markers CD44, CD166, CD133, and CD24 is also consistent with a trend of increasing 
expression in the three stages of maturation. 
In neuroblastoma cells has been demonstrated that hypoxia leads to an 
inhibition of cell differentiation, resulting in maintenance of a stem-like phenotype (51, 
115). Moreover, upon increasing hypoxia an increased expression of genes involved in 
tumor progression namely KRAS, BRAF and SMAD4 was also detectable.  
In conclusion, we have shown that culture of CRC cells from established cell 
lines offers the opportunity to investigate in standardized conditions different MCTS 
stages possibly providing an improved model of “in vivo” tumor growth. 
Data obtained from spheroids at different stages indicate that hypoxia and 
necrosis significantly influence the expression of genes important for tumor 
progression, such as BRAF, KRAS and p53, and encoding putative cancer stem cells 
markers, CD44, CD166, CD24 and CD133. Importantly, the establishment of innovative 
culture systems might be essential not only for a more accurate study of tumor 
progression, but also for the screening of new cancer drugs. 
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Supplementary Table 1 Gene list for the RT-PCR 384 low-density plate 
Gene Symbol Gene name Assay ID Context Sequence 
TP53RK TP53 regulating kinase Hs00369266_m1 TCGCCGCGCTGGAATATCTGCCCCA 
CD44 CD44 molecule (Indian blood group) Hs01075861_m1 TCGAAGAAGGTGTGGGCAGAAGAAA 
18S Eukaryotic 18S rRNA Hs99999901_s1 CCATTGGAGGGCAAGTCTGGTGCCA 
GAPDH glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1 GGGCGCCTGGTCACCAGGGCTGCTT 
ALCAM activated leukocyte cell adhesion molecule Hs00233455_m1 TAGTCAAGGTGTTCAAGCAACCATC 
CD24;CD24P4 CD24 molecule;CD24 molecule pseudogene 4 Hs02379687_s1 GCGGCTGGTGGTGCCCTGCAGTCAA 
EPCAM epithelial cell adhesion molecule Hs00158980_m1 GCTCAGGAAGAATGTGTCTGTGAAA 
LGR5 
leucine-rich repeat-containing G protein-coupled 
receptor 5 
Hs00173664_m1 GCCTTCAATCCCTGCGTCTGGATGC 
EPHB2 EPH receptor B2 Hs01031827_m1 CCTCTCCTCTGGCATCAACCTGCCG 
ALDH1A1 aldehyde dehydrogenase 1 family, member A1 Hs00946916_m1 GCCGACTTGGACAATGCTGTTGAAT 
ALDH3A1 aldehyde dehydrogenase 3 family, member A1 Hs00964880_m1 AAGTCACTGAAAGAGTTCTACGGGG 
SSPN sarcospan (Kras oncogene-associated gene) Hs01025520_m1 TATTCAATTTTCTATGAAACTGTTA 
ABCG5 
ATP-binding cassette, sub-family G (WHITE), 
member 5 
Hs00223686_m1 GTGCTACTGGACGCTGGGCTTACAT 
ABCB1 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 
Hs01067802_m1 ATCGAGTCACTGCCTAATAAATATA 
ABCG2 
ATP-binding cassette, sub-family G (WHITE), 
member 2 
Hs01053790_m1 GGAGGCAAATCTTCGTTATTAGATG 
NANOG Nanog homeobox Hs02387400_g1 GCCTCACACGGAGACTGTCTCTCCT 
POU5F1;POU5F1P
3 
POU class 5 homeobox 1;POU class 5 homeobox 1 
pseudogene 3 
Hs01895061_u1 AGCTGGAGCAAAACCCGGAGGAGTC 
BRAF v-raf murine sarcoma viral oncogene homolog B1 Hs00269944_m1 ATTCCGGAGGAGGTGTGGAATATCA 
TGFBR2 
transforming growth factor, beta receptor II 
(70/80kDa) 
Hs00234253_m1 GCTCAACCACCAGGGCATCCAGATG 
SMAD4 SMAD family member 4 Hs00929647_m1 CCATTGAGAGAGCAAGGTTGCACAT 
PINK1 PTEN induced putative kinase 1 Hs00260868_m1 AGGAGATCCAGGCAATTTTTACCCA 
APC adenomatous polyposis coli Hs01568269_m1 TAAAAAGGAATCAACCCTCAAAAGC 
CEACAM5 
carcinoembryonic antigen-related cell adhesion 
molecule 5 
Hs00944025_m1 CACAGTCTCTGCGGAGCTGCCCAAG 
PROM1 prominin 1 Hs01009250_m1 TTATCGACCCCTTGAATTTGTTTTG 
SOX2OT SOX2 overlapping transcript (non-protein coding) Hs00415716_m1 TCTTTCTATTCCAGGGATTGCAGTG 
TNFRSF10B 
tumor necrosis factor receptor superfamily, 
member 10b 
Hs00366278_m1 TCCCACTGAGACTCTGAGACAGTGC 
TNFSF10 
tumor necrosis factor (ligand) superfamily, 
member 10 
Hs00921974_m1 AGCTGAAGCAGATGCAGGACAAGTA 
BAK1 BCL2-antagonist/killer 1 Hs00940249_m1 AAGATTGCCACCAGGCCAGCAGCAA 
BAX BCL2-associated X protein Hs00180269_m1 CTGGTGCTCAAGGCCCTGTGCACCA 
ITGA2 
integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 
receptor) 
Hs00158127_m1 CTCAGTCAAGGCATTTTAAATTGTT 
ITGA3 
integrin, alpha 3 (antigen CD49C, alpha 3 subunit 
of VLA-3 receptor) 
Hs01076873_m1 AGCACCTTCATCGAGGATTACAGAG 
ITGA5 
integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide) 
Hs01547673_m1 GGAAGTGTTTGGGGAGCAGAACCAT 
ITGA9 integrin, alpha 9 Hs00979865_m1 ATACTGAAAAAGGACAGTTCGTCTG 
ITGAV 
integrin, alpha V (vitronectin receptor, alpha 
polypeptide, antigen CD51) 
Hs00233808_m1 TTCACACTTTGGGTTGTGGAGTTGC 
ITGB4 integrin, beta 4 Hs00236216_m1 GCTGCAAGGCCTGCCTGGCACTTCT 
KLF4 Kruppel-like factor 4 (gut) Hs00358836_m1 CCCGAATAACCGCTGGCGGGAGGAG 
CDH1 cadherin 1, type 1, E-cadherin (epithelial) Hs01023894_m1 CGCGTCCTGGGCAGAGTGAATTTTG 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) Hs00983056_m1 ATCCTGCTTATCCTTGTGCTGATGT 
TWIST1 twist homolog 1 (Drosophila) Hs00361186_m1 CGGAGACCTAGATGTCATTGTTTCC 
SNAI2 snail homolog 2 (Drosophila) Hs00950344_m1 TTAGAACTCACACGGGGGAGAAGCC 
SNAI1 snail homolog 1 (Drosophila) Hs00195591_m1 GACTCTAATCCAGAGTTTACCTTCC 
KRT20 keratin 20 Hs00300643_m1 TCCCATCTCAGCATGAAAGAGTCTT 
MUC2 mucin 2, oligomeric mucus/gel-forming Hs00159374_m1 ACCTGCAAGTCCTGCGTGTGTACCA 
MKI67 antigen identified by monoclonal antibody Ki-67 Hs01032443_m1 CCTGAAGAAAATCATCAAGGAACAG 
PCNA proliferating cell nuclear antigen Hs00696862_m1 TCTTCCCTTACGCAAGTCTCAGCCG 
BMF Bcl2 modifying factor Hs00372937_m1 GACTCTTTTATGGCAATGCTGGCTA 
BIRC5 baculoviral IAP repeat-containing 5 Hs00978503_m1 AACAAAATTGAGAGAGCTCTGTTAG 
FAS Fas (TNF receptor superfamily, member 6) Hs00531110_m1 TCTGGACCCTCCTACCTCTGGTTCT 
ZEB1 zinc finger E-box binding homeobox 1 Hs00232783_m1 TGATGAAAATGGAACACCAGATGCA 
VEGFA vascular endothelial growth factor A Hs00900055_m1 ACATCACCATGCAGATTATGCGGAT 
VEGFB vascular endothelial growth factor B Hs00173634_m1 CCAGTGTGAATGCAGACCTAAAAAA 
VEGFC vascular endothelial growth factor C Hs01099203_m1 AGCTACCTCAGCAAGACGTTATTTG 
HIF1A 
hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor) 
Hs00936371_m1 CAAGAAAAAGATAAGTTCTGAACGT 
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EPAS1 endothelial PAS domain protein 1 Hs01026149_m1 TCACCAGAACTTGTGCACCAAGGGT 
EGF epidermal growth factor Hs01099999_m1 TGGACAAGTATGCATGCAACTGTGT 
IGF1 insulin-like growth factor 1 (somatomedin C) Hs01547656_m1 TTATTTCAACAAGCCCACAGGGTAT 
IGF2 insulin-like growth factor 2 (somatomedin A) Hs00171254_m1 CGGCTTCCAGACACCAATGGGAATC 
IL8 interleukin 8 Hs00174103_m1 GTGTGAAGGTGCAGTTTTGCCAAGG 
IL6 interleukin 6 (interferon, beta 2) Hs00985639_m1 TCAGCCCTGAGAAAGGAGACATGTA 
MMP1 matrix metallopeptidase 1 (interstitial collagenase) Hs00899658_m1 AAGTCCGGTTTTTCAAAGGGAATAA 
FLT1 
fms-related tyrosine kinase 1 (vascular endothelial 
growth factor/vascular permeability factor 
receptor) 
Hs00176573_m1 GACTTAAACTGGGCAAATCACTTGG 
KDR 
kinase insert domain receptor (a type III receptor 
tyrosine kinase) 
Hs00911700_m1 ACACAGCAGGAATCAGTCAGTATCT 
FLT4 fms-related tyrosine kinase 4 Hs01047677_m1 TGGCCGCCAGGTATTACAACTGGGT 
EGFR epidermal growth factor receptor Hs01076078_m1 GAGGAAAAGAAAGTTTGCCAAGGCA 
ERBB2 
v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2, neuro/glioblastoma derived oncogene 
homolog (avian) 
Hs01001580_m1 CTGTTTTGGACCGGAGGCTGACCAG 
MMP2 
matrix metallopeptidase 2 (gelatinase A, 72kDa 
gelatinase, 72kDa type IV collagenase) 
Hs01548727_m1 ACCAGATCACATACAGGATCATTGG 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) Hs01042796_m1 GTAGCAGTCTAGGGATTAACTTCCT 
MMP9 
matrix metallopeptidase 9 (gelatinase B, 92kDa 
gelatinase, 92kDa type IV collagenase) 
Hs00234579_m1 AGTACCGAGAGAAAGCCTATTTCTG 
MMP14 matrix metallopeptidase 14 (membrane-inserted) Hs00237119_m1 GCCCCGAAGCCTGGCTACAGCAATA 
TIMP2 TIMP metallopeptidase inhibitor 2 Hs00234278_m1 TCTCATTGCAGGAAAGGCCGAGGGG 
TIMP3 TIMP metallopeptidase inhibitor 3 Hs00165949_m1 CTCCGACATCGTGATCCGGGCCAAG 
TIMP4 TIMP metallopeptidase inhibitor 4 Hs00162784_m1 GTATCTCTTGACTGGTCAGGTCCTC 
ERBB3 
v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 3 (avian) 
Hs00176538_m1 AACTCTCAGGCAGTGTGTCCTGGGA 
CXCL16 chemokine (C-X-C motif) ligand 16 Hs00222859_m1 GATCTCAAAGAATGTGGACATGCTT 
CX3CL1 chemokine (C-X3-C motif) ligand 1 Hs00171086_m1 GCTGGCTGGACAGCACCACGGTGTG 
PTGS2 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase) 
Hs00153133_m1 CTGGGCCATGGGGTGGACTTAAATC 
PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa Hs00168754_m1 GCTCCTTGCCTTTCACGATTTTTGC 
PTGER4 prostaglandin E receptor 4 (subtype EP4) Hs00168761_m1 TCCATCCCGCTCGTGGTGCGAGTAT 
IDO1 indoleamine 2,3-dioxygenase 1 Hs00984148_m1 TTCTGCAATCAAAGTAATTCCTACT 
LEF1 lymphoid enhancer-binding factor 1 Hs00212390_m1 GGACACGAGGTGGCCAGACAAGCAC 
AXIN1 axin 1 Hs00394718_m1 CGGACAGCAGCGTGGATGGGATCCC 
AXIN2 axin 2 Hs00610344_m1 CCTCATTTCCCGAGAACCCACCGCC 
TLE4 
transducin-like enhancer of split 4 (E(sp1) 
homolog, Drosophila) 
Hs00419101_m1 TCAATACCACAGTCTGAAGCTGGAA 
ERBB4 
v-erb-a erythroblastic leukemia viral oncogene 
homolog 4 (avian) 
Hs00955525_m1 TGCCAGACTTTGACAAGGACGGTGT 
NOTCH1 notch 1 Hs01062011_m1 CGCGGGCCTGATGGCTTCACCCCGC 
JAG1 jagged 1 Hs00164982_m1 TGACACCGTTCAACCTGACAGTATT 
HES1 hairy and enhancer of split 1, (Drosophila) Hs00172878_m1 CGCAGATGACGGCTGCGCTGAGCAC 
HES4 hairy and enhancer of split 4 (Drosophila) Hs00368353_g1 CAGGTGACGGCCGCGCTCAGCGCCG 
HES6 hairy and enhancer of split 6 (Drosophila) Hs00936587_g1 CCGGGCGCGCGAGCGCGAGCAGCTG 
FCGR1A;FCGR1C 
Fc fragment of IgG, high affinity Ia, receptor 
(CD64);Fc fragment of IgG, high affinity Ic, 
receptor (CD64) 
Hs02340031_m1 CAAGTGCTTGGCCTCCAGTTACCAA 
CXCL12 chemokine (C-X-C motif) ligand 12 Hs00171022_m1 CTTCAGATTGTAGCCCGGCTGAAGA 
CCL5 chemokine (C-C motif) ligand 5 Hs00174575_m1 CCAACCCAGCAGTCGTCTTTGTCAC 
CXCL10 chemokine (C-X-C motif) ligand 10 Hs00171042_m1 TGGCATTCAAGGAGTACCTCTCTCT 
CXCL9 chemokine (C-X-C motif) ligand 9 Hs00171065_m1 GTGCAAGGAACCCCAGTAGTGAGAA 
CXCR4 chemokine (C-X-C motif) receptor 4 Hs00237052_m1 CATGGAGGGGATCAGTATATACACT 
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Supplementary Figure 1 Live and Dead staining on HT29 MCTSs (size bar: Stage 1 100x; Stage2 200x; 
Stage 3 400x) 
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In an increasing number of cancers, CSCs have been defined on the basis of the 
self-renewal and tumor initiation capacity by functional assays. It has been also 
suggested that CSC populations might be responsible for chemo- and radio-therapy 
resistance within tumors and ultimately for the post-therapeutic tumor recurrence. 
The development of more effective cancer therapies may thus require targeting this 
important cell population. 
In the past five years, CD133, CD44 and CD166 have been proposed as putative 
CSC markers in CRC. These findings have opened the field for an extensive validation of 
the markers and their use for the development of specific anti-CSC therapy. 
However, the phenotypic characterization of CRC-SC is still debated. We, 
therefore, attempted to extend the knowledge on CSC markers in order to validate 
their clinical relevance, and to evaluate the possibility to isolate putative CSCs from 
established CRC cell lines in order to assess their potential suitability for drug screening 
purposes.  
 
Our studies lead to a number of important conclusions. First, increased 
expression of CD133, CD166, and CD44 putative CSC markers does not appear to be 
associated with unfavorable prognosis, as established by analyzing a substantial 
number of clinically annotated CRC. Rather, a loss of expression of CD166 and CD44, 
and in particular the loss of both markers, appears to be associated with an aggressive 
tumor phenotype. 
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CSCs are also called cancer initiating cells for their capacity to recapitulate 
tumors in mouse model as xenograft. The evaluation of this specific feature represents 
the gold standard used to identify the CSC phenotype. We assessed the tumor 
initiating capacity of primary cells isolated from CRC specimens hypothesizing that the 
presence of high percentages of CSCs within the samples might be correlated with a 
higher ability to engraft in immunodeficient mice. We did not observe a relation 
between tumorigenic capacity and the expression of putative CSC markers. We 
showed, instead, cells expressing these markers are not a small subpopulation within a 
tumor but they could represent substantial percentages of cells within the epithelial 
compartment.  
We also investigated the usefulness of CRC cell lines for the development of 
novel CSC-targeted treatments. However, whether tumor cell lines comprise CSC-
populations remains highly debated. We first assessed the surface expression of 
CD133, CD166, CD44, and CD24 on ten established human CRC cell lines. These results 
showed that the expression of CSC markers is highly heterogeneous and not restricted 
to small cell subsets raising the question of whether the cell lines consist of only CSC 
and about the validity of CSC markers for in vitro studies using cell lines. Furthermore, 
we have analyzed their correlation with stem cell-like functional features, but no 
consistent results was found confirming stemness property associated with expression 
of those markers. 
These results obviously question the validity of putative surface CRC-SC 
markers. Taken together these data might suggest that their expression and CSC 
functional features might be associated with some degree of plasticity, potentially 
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related to tumor microenvironmental characteristics being lost in conventionally 
cultured tumor cell lines and in primary tumor derived cell suspensions. 
 
 
 
Based on this background we have investigated the possibility to perform 3D 
culture of CRC cell lines to assess whether these systems might provide useful insights 
for the interpretation of our data. Our findings clearly document the plasticity of gene 
expression profiles of cultured CRC cells depending on their three-dimensional 
architectures. Most importantly we demonstrate that major gene expression 
modulation events only occur when culture in MCTS is associated with ischemia and 
necrosis. Indeed, as compared to 2D gene expression profile, 3D culture per se 
appeared not to be sufficient to change the gene expression profile of the cell lines 
investigated. However, with the increase of MCTS diameter a gradient of nutrient, 
oxygen, and catabolites occurs altering gene expression profiles in ways matching 
those detectable in xenografts. We also showed that the gene expression of putative 
CSC markers increases with the MCTS size. Future studies are warranted to assess 
whether this ischemia/necrosis related plasticity is also associated with improved 
tumor transplantation ability. 
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